Medicament, dental material, and method of screening

Abstract

The present invention provides a novel and creative dental materials for treatment of pulpitis and/or enhancement of dentinogenesis. The dental materials of the present invention contain at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein as an active ingredient. The dental materials of the present invention contain a carrier having biocompatibility. The dental materials of the present invention can contain at least one cell type among pulp cells, pulp stem cells, pulp progenitor cells, odontoblasts or cells that can differentiate into odontoblasts.

1 . Medicaments for treatment of pulpitis and/or enhancement of dentinogenesis comprising:
 at least one of a protein having matrix metalloprotease 3 activity or matrix metalloprotease 3 precursor protein as an active ingredient.   
     
     
         2 . The medicaments for treatment of pulpitis and/or enhancement of dentinogenesis of  claim 1 , wherein
 the ratio of the active ingredient including at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein is 12 ng/ml-1000 ng/ml.   
     
     
         3 . A dental materials comprising:
 at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein as an active ingredient.   
     
     
         4 . The dental materials of  claim 3 , wherein
 the dental materials include a carrier having biocompatibility.   
     
     
         5 . The dental materials of  claim 4 , wherein
 the carrier is to have at least on one side a plurality of recesses which depth and orientation direct to a constant course, and to be membranous structure consisting of materials having oxygen permeability and/or material permeability.   
     
     
         6 . The dental materials of  claim 4 , wherein
 the carrier has at least one of collagen, artificial proteoglycan, glycosaminoglycan, gelatine, hydrogel, fibrin, phosphophoryn, hyaluronic acid, chitin, glucosamine, fibronectin, alginic acid, heparan sulfate, heparin, laminin, tricalcium phosphate, hydroxyapatitte, β-TCP, polylactic acid, polyglycolic acid, poly-DL-lactic acid, lactic acid glycolic acid copolymer, polyethylene glycol, polysilicon, polycaprolactone, calcium carbonate, titanium, gold, ceramics, silicone resin or silicon hydrogel.   
     
     
         7 . The dental materials of  claim 3 , wherein
 the dental materials have at least one of pulp cells, pulp stem cells, pulp progenitor cells, odontoblasts or cells that can differentiate into odontoblasts.   
     
     
         8 . The dental materials of  claim 7 , wherein
 the cells having at least one of pulp cells, pulp stem cells, pulp progenitor cells, odontoblasts or cells that can differentiate into odontoblasts is more than 1×10 3  cells/μl and lower than 1×10 6  cells/μl.   
     
     
         9 . The dental materials of  claim 3 , wherein
 the dental materials include endothelial cells or endothelial progenitor cells.   
     
     
         10 . The dental materials of  claim 3 , wherein
 the dental materials include epithelium.   
     
     
         11 . The dental materials of  claim 3 , wherein
 the dental materials include dentin matrix.   
     
     
         12 . The dental materials of  claim 3 , wherein
 the ratio of the active ingredient including at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein is 12 ng/ml-1000 ng/ml.   
     
     
         13 . The dental materials of  claim 7 , wherein
 the pulp stem cells have at least one of pulp SP cells, CD31-negative and CD146-negative cells, CD24-positive cells, CD105 positive cells or CD150 positive cells.   
     
     
         14 . A screening method of the active ingredients of the medicaments for treatment of pulpitis and/or acceleration of dentin formation, comprising:
 (1) a step for measuring gene expression of matrix metalloprotease 3 in pulp stem cells or endothelial cells to which test compounds are supplied,   (2) a step for measuring gene expression of matrix metalloprotease 3 in pulp stem cells or endothelial cells to which test compounds are not supplied, and   (3) a step for choosing the compound which increase gene expression of matrix metalloprotease 3 when compared in both matrix metalloprotease 3 expression, as an active ingredient of medicaments.